ACO/ARO/AIO-18.1 Short-course Radiotherapy Versus Chemoradiotherapy, Followed by Consolidation Chemotherapy, and Selective Organ Preservation for MRI-defined Intermediate and High-risk Rectal Cancer Patients (Aktiv)
Erstlinie
ACO/ARO/AIO-21 Capecitabine-based Chemoradiotherapy in Combination With the IL-1 Receptor Antagonist Anakinra for Rectal Cancer Patients (Aktiv)
COCSTOM Randomised trial comparing completeness of adjuvant chemotherapy after early vs. late diverting stoma closure in low anterior resection for rectal cancer (Aktiv)
GSK219369 AZUR A Phase 2, Single-Arm, Open-Label Study with Dostarlimab Monotherapy in Participants with Untreated Stage II/III dMMR/MSI-H Locally Advanced Rectal Cancer (Aktiv)
HyRec Neoadjuvant chemoradiation with 5-FU (or capecitabine) and oxalliplatin combined with deep regonal hyperthermia (Aktiv)
Zweitlinie oder später
BNT122-01 Phase II Studie zu RO7198457 als Zweitlinientherapie bei Dickdarmkrebs und mit erhöhtem Risiko für eine Krankheitsprogression (Aktiv)
RADIANCE Radiochemotherapy +/- Durvalumab for Locally-advanced Anal Carcinoma. A Multicenter, Randomized, Phase II Trial of the German Anal Cancer Study Group (RADIANCE) (Aktiv)
SPOTLIGHT A Phase 3, Global, Multi-Center, Double-Blind, Randomized, Efficacy Study of Zolbetuximab (IMAB362) Plus mFOLFOX6 Compared with Placebo Plus mFOLFOX6 as First-line Treatment of Subjects with Claudin (CLDN)18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (Aktiv)
SUNLIGHT study Eine offene, randomisierte Phase-III-Studie zum Vergleich Trifluridin/Tipiracil in Kombination mit Bevacizumab zu Trifluridin/Tipiracil-Monotherapie bei Patienten mit refraktärem metastasierender Dickdarmkrebs (SUNLIGHT-Studie) (Aktiv)